Please find the enclosed intimation of the Company as per the captioned subject for your reference.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
AstraZeneca Pharma India reported strong full-year results for FY2025-26 ending March 2026. Total revenue from operations grew 32.6% to Rs 22,755.8 Mn from Rs 17,162.9 Mn in the prior year. Profit after tax jumped 62% to Rs 1,875.2 Mn from Rs 1,157.4 Mn. The Board also recommended a dividend of Rs 36 per share (Rs 900 Mn total). The company appointed M/s. BSR & Co. LLP as new Statutory Auditors for 5 years from the conclusion of the ensuing AGM, succeeding M/s. Price Waterhouse Cooper who completed their term. Ms. Shilpa Divekar Nirula was re-appointed as Non-Executive Independent Director for a second 5-year term from December 2026. Exceptional items of Rs 52.5 Mn related to the Bangalore manufacturing site closure were incurred during the year. Operating cash flow turned negative at Rs 151 Mn due to a large inventory build-up of Rs 4,788 Mn.
Strong 33% revenue growth and 62% PAT growth are positive signals for the stock. However, negative operating cash flow and inventory build-up may raise concerns about working capital management. The dividend of Rs 36 per share provides direct shareholder returns.